FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2885424049> ?p ?o ?g. }

• W2885424049 endingPage "A005" @default.
• W2885424049 startingPage "A005" @default.
• W2885424049 abstract "Abstract Non-Hodgkin's lymphomas (NHL) and acute myeloid leukemias (AML) initially respond to chemo- or biologic therapy; however, some develop resistance, becoming aggressively growing tumors. The purpose of our study was the establishment of new PDX models from patients with lymphomas and AML, confirmation of the therapy resistance phenotype, and search for molecular biomarkers. NHL-PDX were generated from samples of the peripheral blood, lymph node extirpations, or fine-needle biopsies. From 76 patient samples, we successfully established 13 subcutaneously growing NHL-PDX from B-cell type and 3 from the T-cell type on immune-deficient mice (NOG/NMRI nu/nu mice). Established PDX models from NHL patients were treated with standard-of-care (SoC) drugs such as cyclophosphamide, vincristine, doxorubicin, and rituximab as well as drugs for the second-line treatment such as gemcitabine or etoposide. AML-PDX were derived from bone marrow aspirates or peripheral blood samples, obtained from primary or relapsed AML patients. Purified leukemia cells were transplanted either intravenously (i.v.) and/or subcutaneously (s.c.) into immune-deficient mice. The mice developed a systemic AML, which was monitored by regular flow cytometric analysis of blood samples. Mice were sacrificed when signs of disease were obvious and single-cell suspensions of spleens (i.v.) or tumor fragments (s.c.) were transferred to new recipient mice. Results from the drug screening revealed a correlation of the PDX model response and treatment resistance in patients. Gene expression as well as mutations were analyzed in the PDX of lymphomas and AML within the first in vivo passages. In summary, two panels of new PDX models from primary and aggressive NHLs and AMLs have been established. Different mutations were found in the PDX tumors. Similar to the patients, those PDX models showed different sensitivity to SoC treatment. We established a new systemic AML PDX by i.v. inoculation. Tracking of human leukemia cells in the blood from the mice allows early evaluation of treatment effects. These new PDX panels of extensively characterized NHL and AML subtypes provide an exceptional platform for the identification and validation of new targets and biomarkers, screening of new compounds and combinations, and for translational as well as personalized oncology research. Citation Format: Bernadette Brzezicha, Antje Siegert, Leonid Karawajew, Clemens Schmitt, Wolfgang Walther, Martin Janz, Iduna Fichtner, Jens Hoffmann. Drug screening in patient-derived xenografts from acute myeloic leukemia and non-Hodgkin's lymphoma shows correlation with chemotherapy resistance in patients [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2017 Oct 26-30; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A005." @default.
• W2885424049 created "2018-08-22" @default.
• W2885424049 creator A5002682008 @default.
• W2885424049 creator A5015081490 @default.
• W2885424049 creator A5031474036 @default.
• W2885424049 creator A5043624610 @default.
• W2885424049 creator A5062669259 @default.
• W2885424049 creator A5074463005 @default.
• W2885424049 creator A5085663844 @default.
• W2885424049 creator A5090624000 @default.
• W2885424049 date "2018-01-01" @default.
• W2885424049 modified "2023-10-02" @default.
• W2885424049 title "Abstract A005: Drug screening in patient-derived xenografts from acute myeloic leukemia and non-Hodgkin's lymphoma shows correlation with chemotherapy resistance in patients" @default.
• W2885424049 doi "https://doi.org/10.1158/1535-7163.targ-17-a005" @default.
• W2885424049 hasPublicationYear "2018" @default.
• W2885424049 type Work @default.
• W2885424049 sameAs 2885424049 @default.
• W2885424049 citedByCount "0" @default.
• W2885424049 crossrefType "journal-article" @default.
• W2885424049 hasAuthorship W2885424049A5002682008 @default.
• W2885424049 hasAuthorship W2885424049A5015081490 @default.
• W2885424049 hasAuthorship W2885424049A5031474036 @default.
• W2885424049 hasAuthorship W2885424049A5043624610 @default.
• W2885424049 hasAuthorship W2885424049A5062669259 @default.
• W2885424049 hasAuthorship W2885424049A5074463005 @default.
• W2885424049 hasAuthorship W2885424049A5085663844 @default.
• W2885424049 hasAuthorship W2885424049A5090624000 @default.
• W2885424049 hasConcept C121608353 @default.
• W2885424049 hasConcept C126322002 @default.
• W2885424049 hasConcept C2776694085 @default.
• W2885424049 hasConcept C2776755627 @default.
• W2885424049 hasConcept C2778119113 @default.
• W2885424049 hasConcept C2778476748 @default.
• W2885424049 hasConcept C2779338263 @default.
• W2885424049 hasConcept C2779429289 @default.
• W2885424049 hasConcept C2779725641 @default.
• W2885424049 hasConcept C2780007613 @default.
• W2885424049 hasConcept C2780653079 @default.
• W2885424049 hasConcept C2780849966 @default.
• W2885424049 hasConcept C502942594 @default.
• W2885424049 hasConcept C71924100 @default.
• W2885424049 hasConceptScore W2885424049C121608353 @default.
• W2885424049 hasConceptScore W2885424049C126322002 @default.
• W2885424049 hasConceptScore W2885424049C2776694085 @default.
• W2885424049 hasConceptScore W2885424049C2776755627 @default.
• W2885424049 hasConceptScore W2885424049C2778119113 @default.
• W2885424049 hasConceptScore W2885424049C2778476748 @default.
• W2885424049 hasConceptScore W2885424049C2779338263 @default.
• W2885424049 hasConceptScore W2885424049C2779429289 @default.
• W2885424049 hasConceptScore W2885424049C2779725641 @default.
• W2885424049 hasConceptScore W2885424049C2780007613 @default.
• W2885424049 hasConceptScore W2885424049C2780653079 @default.
• W2885424049 hasConceptScore W2885424049C2780849966 @default.
• W2885424049 hasConceptScore W2885424049C502942594 @default.
• W2885424049 hasConceptScore W2885424049C71924100 @default.
• W2885424049 hasIssue "1_Supplement" @default.
• W2885424049 hasLocation W28854240491 @default.
• W2885424049 hasOpenAccess W2885424049 @default.
• W2885424049 hasPrimaryLocation W28854240491 @default.
• W2885424049 hasRelatedWork W2047930003 @default.
• W2885424049 hasRelatedWork W2058154950 @default.
• W2885424049 hasRelatedWork W2127682234 @default.
• W2885424049 hasRelatedWork W2183352065 @default.
• W2885424049 hasRelatedWork W2252336101 @default.
• W2885424049 hasRelatedWork W2293389072 @default.
• W2885424049 hasRelatedWork W2368204729 @default.
• W2885424049 hasRelatedWork W2374533761 @default.
• W2885424049 hasRelatedWork W2412181118 @default.
• W2885424049 hasRelatedWork W4236815493 @default.
• W2885424049 hasVolume "17" @default.
• W2885424049 isParatext "false" @default.
• W2885424049 isRetracted "false" @default.
• W2885424049 magId "2885424049" @default.
• W2885424049 workType "article" @default.